Boston Scientific

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of iRhythm

Retrieved on: 
Wednesday, April 3, 2024
Zio, Advertising, Boston Scientific, J. P. Morgan, Growth, Patient, Subpoena duces tecum, LLP, DOJ, Justice, Marketing, FDA, Court, IRTC, Pharmaceutical industry

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia.

Key Points: 
  • Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia.
  • The firm has recovered hundreds of millions of dollars for investors since its founding in 1995.
  • As a result of these misrepresentations, the price of iRhythm common stock traded at artificially inflated prices throughout the Class Period.
  • Faruqi & Faruqi, LLP also encourages anyone with information regarding iRhythm’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of iRhythm

Retrieved on: 
Thursday, March 28, 2024
Zio, Advertising, Boston Scientific, J. P. Morgan, Growth, Patient, Subpoena duces tecum, LLP, DOJ, Justice, Marketing, FDA, Court, IRTC, Pharmaceutical industry

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia.

Key Points: 
  • Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia.
  • The firm has recovered hundreds of millions of dollars for investors since its founding in 1995.
  • As a result of these misrepresentations, the price of iRhythm common stock traded at artificially inflated prices throughout the Class Period.
  • Faruqi & Faruqi, LLP also encourages anyone with information regarding iRhythm’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of iRhythm

Retrieved on: 
Tuesday, March 19, 2024
Zio, Advertising, Boston Scientific, J. P. Morgan, Growth, Patient, Subpoena duces tecum, LLP, DOJ, Justice, Marketing, FDA, Court, IRTC, Pharmaceutical industry

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia.

Key Points: 
  • Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia.
  • The firm has recovered hundreds of millions of dollars for investors since its founding in 1995.
  • As a result of these misrepresentations, the price of iRhythm common stock traded at artificially inflated prices throughout the Class Period.
  • Faruqi & Faruqi, LLP also encourages anyone with information regarding iRhythm’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

Genius Group and OpenExO Sign Merger Agreement, Accelerating Plans to Build Global AI Education Group

Retrieved on: 
Monday, March 18, 2024
Organization, Boston Scientific, Acceleration, Education, AGI, AI, Human, Student, Founding, City, P&G, Ecosystem, Exo, Consultant, Singularity Group, Computer, Vodacom

This merger accelerates our plan to build a worldwide AI Education Group serving a global network of 100 Genius Cities and prepare 100 million students for our exponential future.

Key Points: 
  • This merger accelerates our plan to build a worldwide AI Education Group serving a global network of 100 Genius Cities and prepare 100 million students for our exponential future.
  • Salim is the author of the international bestseller “Exponential Organizations” and “Exponential Organizations 2.0, The New Playbook for 10x Growth & Impact”.
  • Salim serves on the Board of XPRIZE Foundation, which uses large-scale global incentive competitions to crowdsource solutions to the world’s grand challenges.
  • Genius Group’s CEO, Roger Hamilton said “Genius Group has recently announced plans to launch our Genius City model in Singapore, Dubai, Abu Dhabi.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against iRhythm, Hut 8, and Amplitude and Encourages Investors to Contact the Firm

Retrieved on: 
Friday, March 15, 2024
Bitcoin, Research, Amplitude, Zio, Bankruptcy, Boston Scientific, J. P. Morgan, Growth, Acceleration, Atrial fibrillation, COVID-19, Patient, Subpoena duces tecum, Defendant, Stroke, News, Data mining, DOJ, Heart failure, Hut 8, P.C, Justice, Marketing, FDA, IRTC, ECG, Mergers and acquisitions, Cryptocurrency

The Company’s principal product is a monitoring patch that provides electrocardiogram (“ECG”) monitoring for up to 14 days, called Zio XT.

Key Points: 
  • The Company’s principal product is a monitoring patch that provides electrocardiogram (“ECG”) monitoring for up to 14 days, called Zio XT.
  • The Zio XT is intended for non-critical patients, as it does not provide real-time reporting.
  • These types of heart monitors that are approved for high-risk patients and provide near real-time alerts are also referred to as “real-time” monitors.
  • As a result of these misrepresentations, the price of iRhythm common stock traded at artificially inflated prices throughout the Class Period.

SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of iRhythm

Retrieved on: 
Thursday, March 14, 2024
Zio, Advertising, Boston Scientific, J. P. Morgan, Growth, Patient, Subpoena duces tecum, LLP, DOJ, Justice, Marketing, FDA, Court, IRTC, Pharmaceutical industry

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia.

Key Points: 
  • Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia.
  • The firm has recovered hundreds of millions of dollars for investors since its founding in 1995.
  • As a result of these misrepresentations, the price of iRhythm common stock traded at artificially inflated prices throughout the Class Period.
  • Faruqi & Faruqi, LLP also encourages anyone with information regarding iRhythm’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

Protembis Announces First Patient Enrolled in the PROTEMBO IDE Pivotal Trial

Retrieved on: 
Tuesday, April 2, 2024
General Health, Professional Services, Venture Capital, Medical Devices, Hospitals, Small Business, Clinical Trials, Surgery, Cardiology, Biotechnology, Finance, Health, Brain, Boston Scientific, Aortic stenosis, Cerebral arteries, NewYork-Presbyterian Hospital, Patient, Pivotal trial, IDE, Trial of the century, Hospital, DW, TAVR, Study, CEP, Medical imaging

Protembis GmbH (Protembis), a privately-held emerging cardiovascular medical device company, announced today the enrollment of the first patient in the PROTEMBO Investigational Device Exemption (IDE) Pivotal Trial (NCT05873816).

Key Points: 
  • Protembis GmbH (Protembis), a privately-held emerging cardiovascular medical device company, announced today the enrollment of the first patient in the PROTEMBO Investigational Device Exemption (IDE) Pivotal Trial (NCT05873816).
  • The trial will enroll between 250-500 randomized patients undergoing transcatheter aortic valve replacement (TAVR) in the USA and Europe with the ProtEmbo® System, an innovative next generation cerebral embolic protection device (CEP) providing complete 3-vessel coverage of the cerebral arteries.
  • The primary safety endpoint is the rate of major adverse cardiac and cerebrovascular events (MACCE) assessed at 30-days.
  • This significant progress reflects the close collaboration between our study executive committee, our clinical research organization, and core lab partners in planning this complex trial,” said Karl von Mangoldt and Conrad Rasmus Co-CEOs of Protembis.

H.I.G. Capital Acquires the Spine Business of ZimVie Rebranded as Highridge Medical

Retrieved on: 
Monday, April 1, 2024
Banking, Software, General Health, Professional Services, Hardware, Technology, Medical Devices, Other Manufacturing, Health Technology, Finance, Other Technology, Health, Manufacturing, Culture, Boston Scientific, Growth, EVP, Partnership, Patient, Acquisition, Medtronic, H.I.G. Capital, Surgeon, Waters Corporation, CO, J&J, Management

Capital (“H.I.G.”), a leading global alternative investment firm with $60 billion of capital under management, is pleased to announce that one of its affiliates has completed the acquisition of the Spine division of ZimVie, Inc (“ZimVie”, NYSE: ZIMV).

Key Points: 
  • Capital (“H.I.G.”), a leading global alternative investment firm with $60 billion of capital under management, is pleased to announce that one of its affiliates has completed the acquisition of the Spine division of ZimVie, Inc (“ZimVie”, NYSE: ZIMV).
  • The acquired business will operate as an independent entity and has been renamed Highridge Medical (“Highridge” or the “Company”).
  • Glen Kashuba will join Highridge as the Chief Executive Officer and Rebecca Whitney will continue as President of Highridge.
  • medical device investments include Augmedics, Vertiflex (acquired by Boston Scientific), Neuwave Medical (acquired by J&J), and Intact Vascular (acquired by Philips).

Another Giant Stride: ACCELQ Health & Life Science's Vertical Posts Massive Growth Numbers

Retrieved on: 
Tuesday, April 2, 2024
Apps, Applications, Technology, Security, Software, Biotechnology, Health, Pharmaceutical, General Health, Data Management, Test automation, Automation, SOC, SOC 1, Boston Scientific, Specialization, Pfizer, Name, UnitedHealth Group, Quality, DevOps

The development unfolds after successful implementations of test automation for leading health care enterprises, bringing many business benefits to the table.

Key Points: 
  • The development unfolds after successful implementations of test automation for leading health care enterprises, bringing many business benefits to the table.
  • ACCELQ constantly endeavors to reinvent its AI codeless continuous testing platform making itself agile while aligning itself to various unique business and market demands.
  • This leap into the health care services and life sciences domain comes as no surprise after joining hands with renown names in the industry.
  • ACCELQ has catered to the diverse testing requirements of the application stack of health care behemoths.

Protembis Announces Completion of € 30 Million Series B Financing Round and the Addition of Keith D Dawkins MD to the Board of Directors

Retrieved on: 
Tuesday, March 26, 2024
General Health, Professional Services, Venture Capital, Medical Devices, Hospitals, Small Business, Clinical Trials, Cardiology, Biotechnology, Finance, FDA, Health, Brain, Boston Scientific, Growth, Aortic stenosis, Trust, Risk, Patient, Pivotal trial, Research, IDE, Doctor of Philosophy, Stanford University, CMO

Protembis GmbH (Protembis), a privately-held emerging cardiovascular medical device company, announced today the completion of a € 30 million Series B financing round to support the enrollment of the PROTEMBO Investigational Device Exemption (IDE) Pivotal Trial (NCT05873816).

Key Points: 
  • Protembis GmbH (Protembis), a privately-held emerging cardiovascular medical device company, announced today the completion of a € 30 million Series B financing round to support the enrollment of the PROTEMBO Investigational Device Exemption (IDE) Pivotal Trial (NCT05873816).
  • The funding round was structured in two separate capital increases which have both been completed.
  • It was co-led by a European consortium of VC investors including Sweden-based Segulah Medical Acceleration, Italy-based XGEN Venture, and Germany-based TechVision Fund.
  • Other investors include Coparion, several large family offices, angel investors and a multinational medical device strategic.